Opendata, web and dolomites

TherVacB SIGNED

THERVACB: A THERAPEUTIC VACCINE TO CURE HEPATITIS B

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TherVacB project word cloud

Explore the words cloud of the TherVacB project. It provides you a very rough idea of what is the project "TherVacB" about.

boost    jointly    antigens    tanzania    options    africa    clinical    prime    vector    mva    interaction    safety    ip    ib    ethical    occurrence    approved    experts    immune    virology    diagnostic    proving    injections    realized    stigmatize    patients    hepatitis    expressing    trial    burden    found    interdisciplinary    lacking    obtain    adjuvanted    host    cure    spontaneous    track    empirical    preclinical    biomarkers    predict    carries    infectious    vaccination    capacity    particulate    registry    core    immunity    care    human    social    local    hbv    resistance    heterologous    monitoring    neutralizing    95    clinically    form    therapy    protected    tolerance    center    infection    boosted    patient    immunology    excellent    lacks    thervacb    prepare    induce    components    recruitment    secured    antibodies    tackle    breaking    proven    protein    translational    treatment    efficacy    activate    cells    perform    chronic    gt    resolution    therapeutic    polymerase    inducing    tend    models    proof    vaccine    record    of    diseases    cell    innovative    arm    iia    quantify    scheme    first    gmp    virus    media    worldwide   

Project "TherVacB" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 

Organization address
address: INGOLSTADTER LANDSTRASSE 1
city: NEUHERBERG
postcode: 85764
website: www.helmholtz-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 10˙425˙686 €
 EC max contribution 10˙425˙686 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) coordinator 4˙049˙761.00
2    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 1˙394˙787.00
3    CTC NORTH GMBH & CO KG DE (HAMBURG) participant 1˙113˙125.00
4    AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA IT (PARMA) participant 714˙893.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 675˙380.00
6    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 536˙023.00
7    NATIONAL INSTITUTE FOR MEDICAL RESEARCH TZ (DAR ES SALAAM) participant 489˙287.00
8    ARTTIC FR (PARIS) participant 272˙746.00
9    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 209˙350.00
10    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 191˙556.00
11    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 153˙750.00
12    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 146˙500.00
13    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 142˙900.00
14    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 131˙125.00
15    BARTS AND THE LONDON NHS TRUST UK (LONDON) participant 104˙500.00
16    ROYAL FREE LONDON NHS FOUNDATION TRUST UK (LONDON) participant 100˙000.00

Map

 Project objective

Experts in virology, immunology and clinical hepatitis B patient care with an excellent research and translational track record in hepatitis B virus (HBV)-host interaction form the interdisciplinary TherVacB consortium. They jointly tackle the major challenges in HBV therapy – the virus’s resistance to cure. TherVacB aims at breaking immune tolerance in chronic HBV infection and achieving HBV cure. Occurrence of neutralizing antibodies and HBV-specific T cell responses characterize spontaneous resolution of HBV infection that are lacking in chronic infection. We will use our IP-protected heterologous prime-boost therapeutic vaccination scheme with proven efficacy in preclinical models of hepatitis B to target and activate B and T cell responses. Two protein prime injections with clinically approved, adjuvanted particulate HBV S and core protein antigens shall induce neutralizing antibodies and prime T cells that are boosted with an MVA vector expressing HBV core, S, L and polymerase antigens covering >95% of HBV found worldwide. Having secured significant funding and partnerships to obtain GMP-produced vaccine components and to prepare a first-in-human application, TherVacB aims at a clinical proof-of-concept of the therapeutic hepatitis B vaccine in patients with chronic hepatitis B. The consortium will establish a patient registry and perform a multi-center phase Ib/IIa clinical trial that aims at proving safety of the therapeutic vaccine and inducing immune control of chronic HBV infection. One study arm will be realized in Tanzania to build up local capacity, because Africa carries a large burden of HBV infection but lacks diagnostic and therapeutic options. An innovative immune monitoring will quantify HBV-specific immunity and define novel biomarkers to predict treatment response. Finally an ethical and an empirical study will evaluate the recruitment of patients by social media which is very effective for infectious diseases that tend to stigmatize patients

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERVACB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERVACB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More